{"id":83240,"date":"2026-05-28T13:02:31","date_gmt":"2026-05-28T13:02:31","guid":{"rendered":"https:\/\/ciaoup.it\/?p=83240"},"modified":"2026-05-28T13:02:31","modified_gmt":"2026-05-28T13:02:31","slug":"pepromene-bio-announces-oral-presentation-at-eha-2026-highlighting-favorable-safety-and-durable-responses-with-pmb-ct01-baff-r-car-t-cell-therapy-in-b-cell-lymphomas-including-after-prior-cd19-car","status":"publish","type":"post","link":"https:\/\/ciaoup.it\/?p=83240","title":{"rendered":"PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure"},"content":{"rendered":"

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE<\/p>\n

IRVINE, Calif., May 28, 2026 \/PRNewswire\/ — PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association (EHA).\u00a0<\/p>\n

This presentation will highlight results from the completed dose-escalation portion of the study in relapsed\/refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients whose cancer has progressed following standard CD19-directed CAR T-cell therapy (NCT05370430).\u00a0<\/p>\n

Among the nine patients treated in this phase, PMB-CT01 demonstrated a promising safety profile with no dose-limiting toxicities, no grade >1 cytokine release syndrome (CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR). At the last data cutoff, no relapses had occurred and all responses remained ongoing, with the longest response exceeding 3 years. Responding patients also achieved minimal residual disease (MRD)-negative status, indicating deep remissions with no detectable residual cancer cells.\u00a0<\/p>\n

Building on these results, the trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL). Importantly, the first patient treated in this expansion phase \u2013 a patient with transformed FL (tFL) who had progressed following CD19 CAR T therapy \u2013 achieved a CR at their first disease assessment. tFL is an aggressive form of lymphoma with limited established treatment options.\u00a0<\/p>\n

“When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical need, with very limited treatment options remaining,” said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. “These durable CRs clinically validate BAFF-R as a novel target, while the favorable safety profile observed to date may support future use in outpatient community oncology settings and further exploration in refractory autoimmune diseases.”\u00a0<\/p>\n

Presentation Details\u00a0<\/p>\n

Abstract Title: Durable responses and favorable safety of BAFF-R CAR T-cells (PMB-CT01) in patients with relapsed\/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease\u00a0<\/p>\n

Abstract:\u00a0EHA-1611 S287
\n\u00a0<\/p>\n

Date\/Time: June 14, 11:00 AM – 12:15 AM CEST\u00a0<\/p>\n

Presenter: Larry W. Kwak, M.D., Ph.D.\u00a0<\/p>\n

About PMB-CT01\u00a0<\/p>\n

PMB-CT01 is a first-in-class BAFF-R-targeted autologous CAR T-cell therapy being evaluated in ongoing Phase 1 trials for relapsed\/refractory B-NHL and relapsed\/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape.\u00a0<\/p>\n

About PeproMene Bio\u00a0<\/p>\n

PeproMene Bio, Inc. is a clinical-stage biotech company in Irvine, California developing novel therapies to treat cancers and immune disorders. For more information, contact Hazel Cheng, Ph.D., COO of PeproMene Bio, Inc. at Hazel.Cheng@pepromenebio.com or visit https:\/\/pepromenebio.com\/.\u00a0<\/p>\n

Forward-Looking Statements\u00a0<\/p>\n

This press release contains forward-looking statements subject to risks and uncertainties, including risks related to clinical development, regulatory outcomes, therapeutic potential, and commercialization. PeproMene Bio, Inc. undertakes no obligation to update forward-looking statements except as required by law.\u00a0<\/p>\n

Logo – https:\/\/mma.prnewswire.com\/media\/1972356\/Pepromene_Bio_Inc__Logo.jpg
\n\u00a0<\/p>\n

View original content:https:\/\/www.prnewswire.co.uk\/news-releases\/pepromene-bio-announces-oral-presentation-at-eha-2026-highlighting-favorable-safety-and-durable-responses-with-pmb-ct01-baff-r-car-t-cell-therapy-in-b-cell-lymphomas-including-after-prior-cd19-car-t-cell-failure-302783626.html
\n\u00a0<\/p>\n

Copyright 2026 PR Newswire. All Rights Reserved.\u00a0<\/p>\n

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi<\/p>\n

—<\/p>\n

immediapress\/pr-newswire<\/p><\/p>\n

\n\t\t<\/a>\n\t\t<\/div>","protected":false},"excerpt":{"rendered":"

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE IRVINE, Calif., May 28, 2026 \/PRNewswire\/ — PeproMene Bio, Inc.…<\/p>\n","protected":false},"author":3,"featured_media":83241,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[23],"class_list":["post-83240","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-comunicati","tag-immediapress"],"_links":{"self":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/83240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=83240"}],"version-history":[{"count":1,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/83240\/revisions"}],"predecessor-version":[{"id":83310,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/83240\/revisions\/83310"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/media\/83241"}],"wp:attachment":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=83240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=83240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=83240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}